Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The phase 3 PEACE study demonstrated a significant reduction in plasma arginine levels, achieving a 76.7% reduction compared to placebo. However, the primary endpoint was biochemical, and secondary endpoints related to motor function showed statistical ambiguity, with confidence intervals crossing zero. Regulatory bodies expressed caution regarding the clinical significance of these findings, indicating that while there is a strong biochemical effect, the evidence for patient-centered outcomes remains uncertain.
Cost effectiveness
The NICE assessment reported a high ICER of £98,804 per QALY, which is above the typical threshold for cost-effectiveness. While the model structure is plausible, it relies heavily on uncertain assumptions regarding long-term benefits and utility values, leading to concerns about the overall economic value of pegzilarginase.
Quality of life
The evidence for HRQoL improvements is limited and lacks statistical significance. NICE and G-BA noted that the quality-of-life results were uncertain, and no robust data quantifying treatment effects on HRQoL were available. Although some exploratory evidence suggests potential benefits, the overall assessment indicates a lack of clear, meaningful improvements.
Supporting Domains
Safety and Adverse Effects
The safety profile of pegzilarginase appears favorable, with a high percentage of treatment-emergent adverse events reported but no discontinuations due to adverse effects. Serious adverse events were less frequent in pegzilarginase patients compared to placebo. However, potential long-term risks and hypersensitivity reactions remain a concern, necessitating careful monitoring.
Comparator Selection
The pivotal trial compared pegzilarginase to placebo, which is relevant given the lack of established pharmacologic alternatives for this condition. However, the absence of active comparators limits the ability to assess comparative efficacy against other potential treatments, such as liver transplantation, which is a significant gap in the evidence.
Patient Population and Subgroups
The trial population included a majority of pediatric patients, which is representative of the diagnosed population. However, the limited representation of adults raises concerns about the generalizability of the findings. Additionally, subgroup analyses were insufficient due to low patient numbers, further limiting the applicability of the results.
Care Pathway Integration
Pegzilarginase can be integrated into existing care pathways with some adjustments, such as monitoring and supervision during administration. The treatment requires specific protocols for initiation and monitoring, which may introduce some implementation challenges but are manageable within current healthcare frameworks.
Resource Use and Cost Implications
The implementation of pegzilarginase is expected to add significant resource requirements, including monitoring and potential hospitalization for hyperammonemia. While the societal burden of ARG1-D is high, the lack of robust data on cost offsets and budget impact raises concerns about the overall economic implications of widespread adoption.
Evidence Quality and Robustness
The evidence base is primarily derived from a single phase 3 trial, which, while rigorous, is limited by a small sample size and short follow-up duration. Regulatory assessments have highlighted concerns regarding the overall certainty of the evidence, particularly for long-term outcomes and patient-centered benefits.
Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term efficacy and safety of pegzilarginase, particularly concerning its impact on survival and quality of life. The evidence is sensitive to various assumptions, and while the treatment addresses an unmet need, the broader implications for equity and access remain unclear.
